No BS Just Facts logo
No BS Just Facts
It might be boring, but it's just the facts.

← All stories · business

Bloomberg

All-or-Nothing Biotech Bets Dented by Rising Treasury Yields

Thursday, October 22, 2026


Biotechnology stock valuations have declined as U.S. Treasury yields increased. Investors typically view biotech companies as higher-risk investments due to their dependence on uncertain drug development outcomes. Rising yields make bonds and other fixed-income securities more attractive relative to volatile equities, which can reduce capital flowing to speculative stocks.

Original reporting:

Next story

AI agents are ready to shop. Some retailers are wary.→